Small molecule drug may prevent chemotherapy resistance
Scientists have discovered a small molecule drug that may stop cancer cells from becoming resistant to chemotherapy. Drug resistance is a major cause of cancer relapse and is responsible for as much as 90% of deaths related to the disease.
The new compound, which was tested in an animal model of melanoma, could make current chemotherapies more powerful. It works by thwarting cancer’s ability to survive, evolve, and adapt to the DNA damage created by traditional chemotherapy drugs like cisplatin.
“Chemotherapies are often effective the first time around, but then the cancers mutate and become resistant to that drug, and the next, and the next,” said senior study co-author Pei Zhou, Ph.D., a professor of biochemistry at Duke University School of Medicine.
“It reminds me of Boggarts, those shapeshifting creatures from Harry Potter that morph from one scary thing to another. The beauty of this approach is that you essentially freeze the Boggart in its current form, so you can kill it off for good.”
The study was published June 6 in Cell.
In their simplest form, cancer cells are normal cells that are growing out of control. Each time these cells divide, the DNA within them must replicate to generate new copies to go inside each new cell. The first chemotherapy drugs were based on the rationale that rapidly growing cancer cells would be more sensitive to damage to their DNA. Drugs like cisplatin are designed to damage DNA, causing the sensitive replication machinery normally tasked with copying each strand to stall. If DNA replication is stalled for too long, cell division halts, and cells die.
The strategy is brutal and effective, even curative in some cases. But long-term, it often fails, as cancer cells figure out a way to proliferate even in the presence of DNA damage.
“The cancer cells often swap out the high fidelity replication machinery, which usually does the copying, with a sloppy replacement that covers up the lesions and moves on,” said Zhou. “As a result, the cells survive, but with mutations in their DNA.”
Because this process, known as translesion synthesis, is a major cause of cancer drug resistance, it has become a major area of study in cancer research. Scientists have identified a key protein involved, named Rev1, and have even disrupted it through genetic means — works done in the laboratories of Graham C. Walker and Michael T. Hemann at MIT, both senior co-authors of this study. However, attempts to do the same with small molecules had never succeeded, presumably because the protein lacked an obvious binding pocket that a potential drug could exploit.
In this study, Zhou and his collaborators at Duke, MIT, and the University of Rhode Island decided to try their luck at finding a small molecule to block or inhibit Rev1. They screened 10,000 small molecule compounds, and were surprised to find that one — a molecule called JH-RE-06 — appeared to do the trick.
The researchers used a technique called x-ray crystallography to visualize the unexpected interactions between Rev1 and JH-RE-06. They found that when Rev1 interacts with JH-RE-06, it pairs up or dimerizes with another copy of itself, creating a binding pocket where there wasn’t one before. When Rev1 is locked up in this dimer, it can no longer help cancer cells survive and attain their shape-shifting powers.
The researchers then tested the new molecule in human cancer cell lines and showed that it enhanced the ability of several forms of chemotherapy to kill cells, while also suppressing their ability to mutate in the presence of DNA-damaging drugs. Finally, they tested it in a mouse model of human melanoma. They found that not only did the tumors stop growing in mice treated with a combination of cisplatin and JH-RE-06, but also that those mice survived longer.
Senior study co-author Jiyong Hong, PhD, a professor of chemistry at Duke, said that they are currently creating versions of JH-RE-06 that have enhanced pharmacologic properties that could make it an even more attractive drug. “This is a great proof of principle that it is possible to target this protein, but we have a lot of work to do to turn this lead compound into a viable candidate that we can take to the clinic.”
The Latest on: Cancer drug resistance
via Google News
The Latest on: Cancer drug resistance
- Zebrafish patient avatars in cancer biology and precision cancer therapyon April 6, 2020 at 8:20 am
This Review outlines the recent advances in the creation of both combinatorial transgenic cancer models in zebrafish and zebrafish patient-derived xenograft models, and argues that these models have ...
- Scientists enhance new way to overcome resistance to targeted cancer treatmentson April 6, 2020 at 7:03 am
Targeted treatments against kinases have been highly successful in patient treatment but the cancer often evolves resistance to therapy—causing the drug to stop working. The new lysine targeting ...
- The HSP90 inhibitor Onalespib exerts synergistic anti-cancer effects when combined with radiotherapy: an in vitro and in vivo approachon April 3, 2020 at 2:14 am
Combining anti-cancer treatments not sequentially, but simultaneously is an appealing approach to maintain clinical efficacy and to overcome the development of therapy resistance 2. The risk of ...
- Novel role of specific histone deacetylase in lung canceron April 2, 2020 at 12:53 pm
However, lung cancer still remains the number one cause of cancer-related morality, leading to approximately 154,000 deaths each year in the United States. Many patients do not respond to these new ...
- Cancer tumors gain drug resistance by eating dead cellson March 31, 2020 at 7:00 am
Researchers have identified a mechanism by which tumors become resistant to cancer drugs. Share on Pinterest Scientists have identified a mechanism in which cancer cells consume other dead cells to ...
- ESSA Pharma Submits IND for EPI-7386 for Prostate Cancer and Provides Business Updateon March 31, 2020 at 4:04 am
VANCOUVER and HOUSTON , March 31, 2020 /CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX, TSX-V: EPI), a pharmaceutical company focused on developing novel therapies for the treatment ...
- New potential drug identified for resistant breast canceron March 30, 2020 at 6:31 am
A team or researchers including an Indian-American researcher, have identified a molecule that can help treat breast cancer, giving hope to patients who have become resistant to traditional therapies.
- Ovarian Cancer Cells’ Dependence on Fat Opens up Potential New Treatmenton March 30, 2020 at 5:00 am
But in the context of treating cancer, Bitler suggested that the drug’s risk would be well within (and even much less than ... Avoiding cell death is at the heart of chemo-resistance as well,” he ...
- New drug shows promise to reverse treatment resistance in advanced multiple myelomaon March 27, 2020 at 4:41 pm
The new drug, called FL118, has previously shown promise when tested on colon and head and neck cancer cells in the lab. This new study, led by Dr Tuna Mutis and funded by Worldwide Cancer Research ...
- New drug could reverse treatment resistance in advanced multiple myelomaon March 27, 2020 at 9:02 am
The new drug, called FL118, has previously shown promise when tested on colon and head and neck cancer cells in the lab. This new study, led by Dr. Tuna Mutis and funded by Worldwide Cancer Research ...
via Bing News